PI3K inhibitors Drug Pipeline Market Research Report 2022: Insights About 100+ Companies and 100+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “PI3K inhibitors – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

PI3K inhibitors Emerging Drugs Chapters

This segment of the PI3K inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PI3K inhibitors Emerging Drugs

Umbralisib: TG Therapeutics

Umbralisib (TGR-1202) is an oral, once daily, dual inhibitor of PI3K delta and CK1 epsilon. Umbralisib has nanomolar potency to the delta isoform of PI3K and high selectivity over the alpha, beta, and gamma PI3K isoforms. Umbralisib also uniquely inhibits casein kinase 1 epsilon (CK1 epsilon), which may have both direct anti-cancer effects and may also modulate T-cell activity associated with immune-mediated adverse events seen with previous PI3K inhibitors. Currently, umbralisib is being evaluated in Phase IIb and Phase III trials in patients with NHL and CLL.

Gedatolisib: Pfizer

Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Pfizer. It works by targeting PI3K/mTOR. The Phase II clinical trials of gedatolisib for treatment of endometrial cancer and colorectal cancer were terminated early due to enrollment issues. It is currently in phase II stage of development.

Parsaclisib: Incyte Corporation

Parsaclisib is a potent, highly selective, next-generation PI3K? inhibitor that is not associated with clinically meaningful transaminitis. It is in phase II stage of development.

YH 25248: Yuhan

YH 25248 is an oral selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, being developed by Yuhan, for the treatment of cancer.

PI3K inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PI3K inhibitors drugs segregated based on following parameters that define the scope of the report.

Major Players in PI3K inhibitors

There are approx. 100+ key companies which are developing the therapies based on PI3K inhibitors. The companies which have their drug candidate based on PI3K inhibitors in the most advanced stage, i.e. phase II/III include TG Therapeutics and others

PI3K inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PI3K inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PI3K inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence PI3K inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• In May 2019, Onconova to receive USD 4 Million upfront, including USD 2 Million Fee and USD 2 Million for Onconova Shares Purchased at a Premium, Plus up to USD 45.5 Million in Regulatory and Sales Milestones for Rigosertib in Greater China.
• In December 2019, Onconova Therapeutics, and Inceptua Medicines announced that they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world

Key Players

• TG Therapeutics
• Pfizer
• Incyte Corporation
• Yuhan
• Inflection Biosciences/AUM Biosciences
• Onconova Therapeutics
• UCB

Key Products

• Umbralisib
• Gedatolisib
• Parsaclisib
• YH 25248

Research Programme: anti-cancer therapeutics

• Rigosertib
• Seletalisib

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/f65gk7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900